Skip to main content

Table 1 The demographic and clinical characteristics of the patients in the two study groups

From: Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

Variable

PDG

PDL

P-value

Mean ± SD

Mean ± SD

 

Age, year

47.8 ± 9.04

43.7 ± 9.23

0.05

BMI, kg/m2

27.8 ± 4.88

26.6 ± 4.06

0.261

Tumor size, cm

3.0 ± 1.1

3.1 ± 0.9

0.744

Excised LN, n

7.9 ± 4.6

8.7 ± 6.1

0.566

Involved LN, n

2.1 ± 2.7

2.1 ± 2.6

0.958

Ki-67, %

36.0 ± 23.2

34.6 ± 26.5

0.819

 

No (%)

No (%)

 

Age

  

0.116

  < 50

24 (60)

30 (75)

 

  ≥ 50

16 (40)

10 (25)

 

Education

  

0.362

 Illiterate/Primary School

16 (42.1)

19 (48.7)

 

 High School Diploma/University Education

22 (57.9)

20 (51.3)

 

Marital status

  

0.387

 Married

33 (82.5)

33 (87.5)

 

 Single/Divorced/Widowed

7 (17.5)

5 (12.5)

 

Employment status

  

0.293

 Housewife

30 (75.5)

33 (82.5)

 

 Employed

10 (25)

7 (17.5)

 

ER

  

0.150

 Negative

11 (28.2)

6 (15.8)

 

 Positive

28 (71.8)

32 (84.2)

 

PR

  

0.061

 Negative

19 (48.7)

11 (28.9)

 

 Positive

20 (51.3)

27 (71.1)

 

HER2

  

0.587

 Negative

31 (79.5)

30 (78.9)

 

 Positive

8 (20.5)

8 (21.1)